Pulmonary Fibrosis · Herbal Medicine
The emerging evidence supporting Salvia miltiorrhiza as a potential treatment for pulmonary fibrosis could disrupt the current therapeutic landscape. Pharma strategy teams should evaluate how traditional herbal medicines might be integrated into their portfolios, especially in light of increasing interest in alternative therapies.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/24/2026, 12:30:47 PM
Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
The emerging evidence supporting Salvia miltiorrhiza as a potential treatment for pulmonary fibrosis could disrupt the current therapeutic landscape. Pharma strategy teams should evaluate how traditional herbal medicines might be integrated into their portfolios, especially in light of increasing interest in alternative therapies. Regulatory context from MHRA (Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis) supports the near-term read. Assessment grounded in 9 ranked evidence items (4 high-relevance).
The strongest clinical anchor is FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (ClinicalTrials.gov), sub-indication match (ild). In ild, 1 regulatory and 4 competitive items passed relevance filtering for pulmonary fibrosis treatments. If Salvia miltiorrhiza proves effective, it could capture market share from existing pulmonary fibrosis treatments, influencing revenue streams for companies involved in this therapeutic area.
The most relevant competitive pressure comes from Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next (Novartis) — sub-indication match (ild); sponsor/company relevance (novartis). Secondary pressure from [Ad hoc announcement pursuant to Art.. This finding may position Salvia miltiorrhiza as a novel therapeutic option in the pulmonary fibrosis space, potentially impacting existing treatments.
Regulatory risk is concentrated around Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis (MHRA). Sub-indication match (ild). The integration of herbal medicines into treatment protocols may necessitate new regulatory considerations, particularly regarding safety and efficacy evaluations.
Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
MHRAhigh relevance
Sub-indication match (ild)
FDA document
View sourceMitigating Risks of Compounded Drugs Through Surveillance
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source[IBENTO][IBENTO]PMDA-ATC Herbal Medicine Seminar 2026
PMDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceUPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceBeekeeper’s Naturals Issues Voluntary Nationwide Recall of Beekeeper’s Naturals Saline Nasal Spray Sold Through Amazon Due to Microbial Contamination
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View sourceAMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Impro
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceNovartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next
Novartishigh relevance
Sub-indication match (ild); Sponsor/company relevance (Novartis)
FDA document
View source[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View sourceConcerns Raised Over Hepatotoxicity of Epimedium brevicornu Maxim.
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Ketamine Trial for Long COVID Symptoms Shows Promise for Fatigue and Brain Fog
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Salvia miltiorrhiza Bunge alleviates pulmonary fibrosis by promoting fibroblast mitophagy.
PubMedhigh relevance
Sub-indication match (ild)
FDA document
View sourceAssociation between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
PubMedmedium relevance
Sub-indication match (ild)
FDA document
View sourceYang-Xue-An-Tai Decoction Treats URSA by regulating the differentiation of proliferating decidual stromal cells through multiple targets.
PubMedmedium relevance
Sub-indication match (ild)
FDA document
View sourcePaeoniae decoction attenuates chronic colitis-associated intestinal fibrosis by suppressing TGF-β/Smad-mediated epithelial-mesenchymal transition and remodeling the metabolic microenvironment.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceTargeting post-translational modifications by traditional Chinese medicine in cerebral ischemia-reperfusion injury: Recent advances.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceThe dual role of exosomes in renal fibrosis and their potential for clinical translational applications.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceOral self-assembly nanoemulsion drives in vivo hepatic stellate cell-targeting drug delivery in liver fibrosis.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceTsamba-stir-fried Tiebangchui: Attenuates the toxicity of raw Tiebangchui without compromising its analgesic efficacy in Caenorhabditis elegans through TRPV channel regulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe emerging evidence supporting Salvia miltiorrhiza as a potential treatment for pulmonary fibrosis could disrupt the current therapeutic landscape. Pharma strategy teams should evaluate how traditional herbal medicines might be integrated into their portfolios, especially in light of increasing interest in alternative therapies.
If Salvia miltiorrhiza proves effective, it could capture market share from existing pulmonary fibrosis treatments, influencing revenue streams for companies involved in this therapeutic area.
The integration of herbal medicines into treatment protocols may necessitate new regulatory considerations, particularly regarding safety and efficacy evaluations.
Monitor further clinical studies and trials evaluating the efficacy of Salvia miltiorrhiza in pulmonary fibrosis.
Track for follow-up milestones; no immediate action required.